Results 91 to 100 of about 37,814 (299)
Acta Ophthalmologica, Volume 103, Issue 3, Page 295-303, May 2025.Abstract Purpose To quantify ellipsoid zone (EZ) loss during anti‐VEGF therapy for neovascular age‐related macular degeneration (nAMD) and correlate these findings with nAMD disease activity using artificial intelligence‐based algorithms. Methods Spectral domain optical coherence tomography (Spectralis, Heidelberg Engineering) images from nAMD ...
Virginia Mares +7 more
wiley +1 more source
Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]
, 2019 The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto +5 more
core +1 more source
JAMA ophthalmology, 2019 Importance To our knowledge, this is the first randomized clinical trial to compare visual outcomes and injection loads between ranibizumab and aflibercept using an identical treat-and-extend (TE) regimen for neovascular age-related macular degeneration (
M. Gillies +7 more
semanticscholar +1 more source
PLoS ONE, 2020 Purpose To assess the one-year effectiveness and safety of ranibizumab 0.5 mg in treatment- naïve patients with diabetic macular edema (DME) enrolled in the real-world LUMINOUS study. Patients and methods A 5-year, prospective, observational, open-label,
P. Mitchell +12 more
semanticscholar +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To investigate whether automated intra‐ and subretinal fluid (IRF/SRF) volume measurements are equivalent to manual evaluations by eye care professionals from different backgrounds on real‐world optical coherence tomography (OCT) images in neovascular age‐related macular degeneration (nAMD).
Martin Michl +10 more
wiley +1 more source
Anti-VEGF for the Management of Diabetic Macular Edema [PDF]
, 2014 Diabetic retinopathy (DR) is an important cause of vision loss around the world, being the leading cause in the population between 20 and 60 years old. Among patients with DR, diabetic macular edema (DME) is the most frequent cause of vision impairment ...
Badaro, Emmerson +5 more
core +2 more sources
Tracking visual outcomes – Follow‐up on patients born preterm with childhood‐onset visual impairment
Acta Ophthalmologica, EarlyView.Abstract Purpose Preterm birth is associated with a risk of ocular complications. The primary aim of the study was to evaluate the main cause of visual impairment (VI) in a cohort of preterm born patients who had childhood‐onset VI. The association between health‐related quality of life (HRQoL) and age, cause—and severity of VI and impairment type was ...
Hajer A. Al‐Abaiji +4 more
wiley +1 more source
EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE. [PDF]
, 2017 To evaluate intravitreal aflibercept in macular telangiectasia Type 1 (MacTel 1) patients and measure their ocular angiogenic profile. Eight subjects with MacTel 1 refractory to bevacizumab, ranibizumab, or laser therapy and switched to aflibercept were ...
Autiero +56 more
core +2 more sources
Senses and Sciences, 2014 Objective: The study compares the effectiveness of an intravitreal slow-release dexamethasone implant respect to an intravitreal injection of a anti-VEGF, ranibizumab, in the treatment of diabetic macular edema (DME).
Elena Pacella +8 more
doaj +1 more source
Acta Ophthalmologica, EarlyView.Abstract The aim of this review was to evaluate the comparative efficacy of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy for neovascular AMD. We searched 12 literature databases for randomised clinical trials (RCT) on anti‐VEGF therapy for neovascular AMD and extracted data on: change from baseline to 12 months in best ...
Emilie T. S. Butler +17 more
wiley +1 more source